Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...

Study findings were mixed regarding the postsurgical combination of Keytruda and chemotherapy with or without radiation among ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Hello Health Rounds Readers! Today we highlight research findings reported at ESMO 2024, the annual meeting of the European ...

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

Recommended Reading Biomarker data help Merck case for wide use of Keytruda combo Merck ... as an add-on to other types of treatment for early-stage lung and skin cancer, the comapny said ...

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...